| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 5 | 2023 | 380 | 2.610 |
Why?
|
| Neoplasms | 14 | 2022 | 1103 | 1.630 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2023 | 149 | 1.480 |
Why?
|
| Cannabis | 2 | 2023 | 79 | 1.410 |
Why?
|
| Smoking | 14 | 2021 | 940 | 1.410 |
Why?
|
| Quality of Life | 10 | 2020 | 481 | 1.330 |
Why?
|
| Early Detection of Cancer | 2 | 2024 | 336 | 1.330 |
Why?
|
| Mesothelioma | 9 | 2023 | 144 | 1.300 |
Why?
|
| Urinary Bladder Neoplasms | 7 | 2023 | 63 | 1.240 |
Why?
|
| Breast Neoplasms | 25 | 2023 | 1502 | 1.220 |
Why?
|
| Survivors | 7 | 2021 | 136 | 1.190 |
Why?
|
| Humans | 107 | 2024 | 37093 | 1.030 |
Why?
|
| Mammography | 14 | 2014 | 188 | 0.950 |
Why?
|
| Adolescent Behavior | 5 | 2021 | 253 | 0.940 |
Why?
|
| Colonoscopy | 1 | 2024 | 104 | 0.920 |
Why?
|
| Female | 79 | 2024 | 20969 | 0.890 |
Why?
|
| Areca | 2 | 2020 | 28 | 0.890 |
Why?
|
| Hawaii | 31 | 2024 | 1929 | 0.840 |
Why?
|
| Respiratory Tract Diseases | 1 | 2022 | 23 | 0.840 |
Why?
|
| HMGB1 Protein | 5 | 2023 | 29 | 0.830 |
Why?
|
| Colorectal Neoplasms | 2 | 2024 | 441 | 0.800 |
Why?
|
| Marijuana Smoking | 1 | 2021 | 85 | 0.730 |
Why?
|
| Information Seeking Behavior | 1 | 2020 | 26 | 0.720 |
Why?
|
| Aged | 36 | 2024 | 6741 | 0.710 |
Why?
|
| Middle Aged | 49 | 2024 | 10129 | 0.700 |
Why?
|
| Male | 45 | 2024 | 20025 | 0.690 |
Why?
|
| Acculturation | 1 | 2020 | 188 | 0.650 |
Why?
|
| Adolescent | 22 | 2023 | 5363 | 0.650 |
Why?
|
| Adult | 43 | 2024 | 11712 | 0.620 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 3 | 2023 | 23 | 0.610 |
Why?
|
| Exercise | 2 | 2019 | 613 | 0.590 |
Why?
|
| Asbestos | 3 | 2023 | 55 | 0.570 |
Why?
|
| Body Composition | 3 | 2021 | 162 | 0.510 |
Why?
|
| Cross-Sectional Studies | 12 | 2021 | 2721 | 0.500 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2020 | 864 | 0.480 |
Why?
|
| Breast | 6 | 2014 | 135 | 0.470 |
Why?
|
| Lung Neoplasms | 4 | 2023 | 358 | 0.470 |
Why?
|
| Premenopause | 9 | 2013 | 104 | 0.460 |
Why?
|
| Risk Factors | 23 | 2023 | 3562 | 0.450 |
Why?
|
| Nipple Aspirate Fluid | 4 | 2013 | 14 | 0.410 |
Why?
|
| Attitude to Health | 3 | 2020 | 325 | 0.410 |
Why?
|
| Complementary Therapies | 2 | 2012 | 46 | 0.410 |
Why?
|
| Young Adult | 15 | 2022 | 4268 | 0.400 |
Why?
|
| Soy Foods | 4 | 2013 | 60 | 0.390 |
Why?
|
| Whole Body Imaging | 2 | 2021 | 25 | 0.370 |
Why?
|
| Prevalence | 11 | 2023 | 1455 | 0.370 |
Why?
|
| Sickness Impact Profile | 2 | 2007 | 21 | 0.340 |
Why?
|
| Aged, 80 and over | 13 | 2021 | 2379 | 0.330 |
Why?
|
| Psychometrics | 3 | 2020 | 318 | 0.320 |
Why?
|
| Ubiquitin Thiolesterase | 3 | 2023 | 52 | 0.310 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2007 | 14 | 0.310 |
Why?
|
| Telemedicine | 2 | 2021 | 182 | 0.300 |
Why?
|
| Anthropometry | 4 | 2021 | 97 | 0.300 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 2 | 2018 | 31 | 0.300 |
Why?
|
| Aid to Families with Dependent Children | 1 | 2007 | 1 | 0.300 |
Why?
|
| Colonic Neoplasms | 2 | 2020 | 186 | 0.290 |
Why?
|
| Morinda | 2 | 2021 | 9 | 0.290 |
Why?
|
| Health Behavior | 5 | 2020 | 537 | 0.280 |
Why?
|
| Neoplasm Staging | 10 | 2021 | 275 | 0.280 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2017 | 253 | 0.270 |
Why?
|
| Absorptiometry, Photon | 3 | 2021 | 75 | 0.270 |
Why?
|
| Breast Feeding | 1 | 2007 | 113 | 0.260 |
Why?
|
| Prognosis | 9 | 2021 | 739 | 0.260 |
Why?
|
| Menthol | 2 | 2015 | 21 | 0.250 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 807 | 0.250 |
Why?
|
| Students | 4 | 2017 | 519 | 0.250 |
Why?
|
| Isoflavones | 5 | 2012 | 129 | 0.250 |
Why?
|
| Cultural Diversity | 2 | 2002 | 169 | 0.240 |
Why?
|
| Plasminogen Activator Inhibitor 2 | 2 | 2022 | 3 | 0.240 |
Why?
|
| United States | 7 | 2021 | 4223 | 0.230 |
Why?
|
| Caregivers | 3 | 2021 | 182 | 0.230 |
Why?
|
| Adaptation, Psychological | 3 | 2017 | 385 | 0.220 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2015 | 214 | 0.220 |
Why?
|
| Prostatic Neoplasms | 2 | 2021 | 935 | 0.210 |
Why?
|
| Quality of Health Care | 2 | 2021 | 138 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2020 | 628 | 0.210 |
Why?
|
| Age Factors | 7 | 2019 | 1033 | 0.210 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2019 | 84 | 0.210 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2023 | 84 | 0.210 |
Why?
|
| BCG Vaccine | 1 | 2022 | 10 | 0.210 |
Why?
|
| Adipose Tissue | 2 | 2021 | 177 | 0.200 |
Why?
|
| Carotenoids | 2 | 2014 | 70 | 0.200 |
Why?
|
| California | 1 | 2023 | 476 | 0.200 |
Why?
|
| Pilot Projects | 6 | 2022 | 661 | 0.200 |
Why?
|
| Prospective Studies | 5 | 2019 | 1378 | 0.200 |
Why?
|
| Reproducibility of Results | 5 | 2022 | 935 | 0.190 |
Why?
|
| Asbestosis | 1 | 2020 | 6 | 0.190 |
Why?
|
| Receptor, erbB-2 | 2 | 2023 | 133 | 0.190 |
Why?
|
| Postmenopause | 5 | 2014 | 128 | 0.190 |
Why?
|
| Health Surveys | 2 | 2020 | 373 | 0.190 |
Why?
|
| Uveal Neoplasms | 1 | 2020 | 9 | 0.180 |
Why?
|
| Germ-Line Mutation | 1 | 2020 | 57 | 0.180 |
Why?
|
| Health Literacy | 1 | 2022 | 105 | 0.180 |
Why?
|
| Activities of Daily Living | 2 | 2013 | 105 | 0.180 |
Why?
|
| RecQ Helicases | 1 | 2020 | 35 | 0.180 |
Why?
|
| Receptors, Calcitriol | 1 | 2021 | 69 | 0.180 |
Why?
|
| Micronesia | 1 | 2020 | 80 | 0.180 |
Why?
|
| Philippines | 5 | 2015 | 73 | 0.180 |
Why?
|
| Estrogens | 2 | 2012 | 202 | 0.180 |
Why?
|
| Knee | 1 | 2019 | 7 | 0.180 |
Why?
|
| Japan | 7 | 2012 | 305 | 0.180 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2023 | 767 | 0.180 |
Why?
|
| Dance Therapy | 1 | 2019 | 5 | 0.180 |
Why?
|
| Health Status Indicators | 2 | 2013 | 75 | 0.180 |
Why?
|
| Population Surveillance | 5 | 2012 | 238 | 0.170 |
Why?
|
| Parity | 2 | 2012 | 46 | 0.170 |
Why?
|
| Kidney Neoplasms | 1 | 2020 | 68 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 182 | 0.170 |
Why?
|
| Registries | 5 | 2017 | 335 | 0.170 |
Why?
|
| Melanoma | 1 | 2020 | 96 | 0.170 |
Why?
|
| Interleukin-15 | 1 | 2019 | 13 | 0.170 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2011 | 8 | 0.170 |
Why?
|
| Vitamin D | 2 | 2013 | 196 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 128 | 0.170 |
Why?
|
| Estrone | 2 | 2011 | 21 | 0.170 |
Why?
|
| Nicotine | 3 | 2018 | 257 | 0.170 |
Why?
|
| Fatigue | 2 | 2017 | 83 | 0.170 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 94 | 0.160 |
Why?
|
| Respiration Disorders | 1 | 2018 | 7 | 0.160 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2020 | 145 | 0.160 |
Why?
|
| Flavoring Agents | 1 | 2018 | 20 | 0.160 |
Why?
|
| Skin Neoplasms | 1 | 2020 | 159 | 0.160 |
Why?
|
| Up-Regulation | 1 | 2021 | 513 | 0.160 |
Why?
|
| Cross-Cultural Comparison | 2 | 2013 | 107 | 0.160 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 190 | 0.160 |
Why?
|
| Aldehydes | 1 | 2018 | 69 | 0.160 |
Why?
|
| Case-Control Studies | 8 | 2014 | 1130 | 0.150 |
Why?
|
| Receptors, Progesterone | 2 | 2011 | 81 | 0.150 |
Why?
|
| Ovarian Neoplasms | 1 | 2021 | 312 | 0.150 |
Why?
|
| Pyruvates | 1 | 2017 | 6 | 0.150 |
Why?
|
| Socioeconomic Factors | 4 | 2019 | 1067 | 0.150 |
Why?
|
| Receptors, Estrogen | 2 | 2011 | 156 | 0.150 |
Why?
|
| Soybean Proteins | 3 | 2011 | 38 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2016 | 9 | 0.140 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2016 | 17 | 0.140 |
Why?
|
| Risk-Taking | 1 | 2020 | 451 | 0.140 |
Why?
|
| Estradiol | 2 | 2011 | 262 | 0.140 |
Why?
|
| Chromosome Deletion | 1 | 2016 | 56 | 0.140 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2016 | 47 | 0.140 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2016 | 27 | 0.140 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2023 | 194 | 0.140 |
Why?
|
| Behavior, Addictive | 1 | 2016 | 32 | 0.140 |
Why?
|
| Mutation | 4 | 2023 | 1095 | 0.140 |
Why?
|
| Proteins | 1 | 2019 | 369 | 0.130 |
Why?
|
| Pleural Neoplasms | 1 | 2016 | 53 | 0.130 |
Why?
|
| Diet | 5 | 2013 | 801 | 0.130 |
Why?
|
| Radiation, Ionizing | 1 | 2015 | 13 | 0.130 |
Why?
|
| Time Factors | 6 | 2011 | 1742 | 0.130 |
Why?
|
| Radiation Injuries | 1 | 2015 | 22 | 0.130 |
Why?
|
| Perception | 3 | 2021 | 195 | 0.130 |
Why?
|
| Infant | 4 | 2015 | 1046 | 0.130 |
Why?
|
| Animals | 9 | 2023 | 15081 | 0.130 |
Why?
|
| Cross-Over Studies | 5 | 2013 | 108 | 0.130 |
Why?
|
| Ubiquinone | 1 | 2014 | 22 | 0.120 |
Why?
|
| Motivation | 1 | 2017 | 436 | 0.120 |
Why?
|
| Mice | 6 | 2023 | 5913 | 0.120 |
Why?
|
| Tocopherols | 1 | 2014 | 65 | 0.120 |
Why?
|
| Environmental Exposure | 1 | 2016 | 216 | 0.120 |
Why?
|
| Vitamin A | 1 | 2014 | 87 | 0.110 |
Why?
|
| Vitamins | 1 | 2014 | 94 | 0.110 |
Why?
|
| Retrospective Studies | 5 | 2020 | 2026 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 251 | 0.110 |
Why?
|
| Survival Rate | 4 | 2011 | 311 | 0.110 |
Why?
|
| Fetal Blood | 1 | 2013 | 50 | 0.110 |
Why?
|
| Mammary Glands, Human | 1 | 2013 | 39 | 0.110 |
Why?
|
| Antibody Affinity | 1 | 2012 | 25 | 0.110 |
Why?
|
| Pregnancy Complications, Parasitic | 1 | 2012 | 12 | 0.110 |
Why?
|
| Physical Fitness | 1 | 2013 | 90 | 0.100 |
Why?
|
| Pregnancy | 4 | 2013 | 1549 | 0.100 |
Why?
|
| Reproductive History | 1 | 2012 | 19 | 0.100 |
Why?
|
| Cause of Death | 1 | 2012 | 156 | 0.100 |
Why?
|
| Antigens, Protozoan | 1 | 2012 | 72 | 0.100 |
Why?
|
| Heterozygote | 2 | 2023 | 93 | 0.100 |
Why?
|
| Nipples | 1 | 2011 | 14 | 0.100 |
Why?
|
| Cohort Studies | 5 | 2011 | 1492 | 0.100 |
Why?
|
| Child | 4 | 2019 | 3131 | 0.100 |
Why?
|
| Urinalysis | 2 | 2022 | 30 | 0.100 |
Why?
|
| Stress, Psychological | 1 | 2017 | 583 | 0.100 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 105 | 0.100 |
Why?
|
| Tobacco Use Disorder | 1 | 2015 | 237 | 0.100 |
Why?
|
| Malaria, Falciparum | 1 | 2012 | 90 | 0.100 |
Why?
|
| Incidence | 5 | 2020 | 922 | 0.090 |
Why?
|
| Emigrants and Immigrants | 1 | 2013 | 137 | 0.090 |
Why?
|
| Logistic Models | 4 | 2019 | 923 | 0.090 |
Why?
|
| Cell Movement | 3 | 2021 | 571 | 0.090 |
Why?
|
| Nutritional Physiological Phenomena | 2 | 2011 | 39 | 0.090 |
Why?
|
| Schools | 3 | 2017 | 260 | 0.090 |
Why?
|
| gamma-Tocopherol | 1 | 2010 | 19 | 0.090 |
Why?
|
| Epithelial Cells | 1 | 2013 | 384 | 0.090 |
Why?
|
| Women's Health | 1 | 2011 | 145 | 0.090 |
Why?
|
| Adiposity | 1 | 2011 | 154 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2016 | 974 | 0.090 |
Why?
|
| Motor Activity | 1 | 2013 | 418 | 0.090 |
Why?
|
| Obesity | 2 | 2010 | 1067 | 0.090 |
Why?
|
| Micronutrients | 1 | 2010 | 44 | 0.090 |
Why?
|
| Nonlinear Dynamics | 2 | 2013 | 33 | 0.080 |
Why?
|
| Scopoletin | 1 | 2009 | 4 | 0.080 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2009 | 9 | 0.080 |
Why?
|
| C-Reactive Protein | 1 | 2010 | 149 | 0.080 |
Why?
|
| Regression Analysis | 4 | 2015 | 455 | 0.080 |
Why?
|
| Longitudinal Studies | 3 | 2022 | 885 | 0.080 |
Why?
|
| Cell Proliferation | 3 | 2021 | 1198 | 0.080 |
Why?
|
| Leptin | 1 | 2010 | 118 | 0.080 |
Why?
|
| Patient Compliance | 1 | 2010 | 212 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 2 | 2022 | 127 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2006 | 400 | 0.080 |
Why?
|
| Odds Ratio | 4 | 2015 | 534 | 0.080 |
Why?
|
| Survival Analysis | 3 | 2021 | 325 | 0.080 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2012 | 404 | 0.080 |
Why?
|
| Phytotherapy | 1 | 2009 | 81 | 0.080 |
Why?
|
| Control Groups | 1 | 2007 | 2 | 0.080 |
Why?
|
| Linear Models | 2 | 2021 | 275 | 0.080 |
Why?
|
| Aging | 1 | 2013 | 664 | 0.080 |
Why?
|
| Child, Preschool | 3 | 2019 | 1418 | 0.080 |
Why?
|
| Sex Factors | 2 | 2019 | 898 | 0.080 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2007 | 23 | 0.080 |
Why?
|
| Proportional Hazards Models | 4 | 2013 | 441 | 0.080 |
Why?
|
| Prolactin | 1 | 2007 | 62 | 0.080 |
Why?
|
| Maternal-Child Health Centers | 1 | 2007 | 4 | 0.070 |
Why?
|
| Inflammation | 2 | 2023 | 618 | 0.070 |
Why?
|
| Nursing Research | 1 | 2007 | 12 | 0.070 |
Why?
|
| Cell Line, Tumor | 3 | 2021 | 2231 | 0.070 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2007 | 70 | 0.070 |
Why?
|
| Healthy People Programs | 1 | 2007 | 23 | 0.070 |
Why?
|
| Likelihood Functions | 1 | 2007 | 59 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2009 | 213 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 562 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2016 | 448 | 0.070 |
Why?
|
| Self Efficacy | 2 | 2019 | 184 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2007 | 180 | 0.070 |
Why?
|
| Interviews as Topic | 1 | 2007 | 381 | 0.070 |
Why?
|
| Mice, Knockout | 2 | 2020 | 933 | 0.070 |
Why?
|
| Internet | 2 | 2017 | 211 | 0.060 |
Why?
|
| Feeding Behavior | 2 | 2007 | 454 | 0.060 |
Why?
|
| Risk | 2 | 2016 | 267 | 0.060 |
Why?
|
| Cotinine | 2 | 2015 | 43 | 0.060 |
Why?
|
| ROC Curve | 2 | 2021 | 138 | 0.060 |
Why?
|
| Progesterone | 1 | 2005 | 113 | 0.060 |
Why?
|
| Cultural Characteristics | 1 | 2005 | 125 | 0.060 |
Why?
|
| Depression | 2 | 2017 | 712 | 0.060 |
Why?
|
| Alcohol Drinking | 2 | 2007 | 519 | 0.060 |
Why?
|
| Life Style | 1 | 2007 | 308 | 0.060 |
Why?
|
| Body Mass Index | 4 | 2011 | 854 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2005 | 84 | 0.060 |
Why?
|
| Demography | 1 | 2004 | 175 | 0.060 |
Why?
|
| Saliva | 2 | 2015 | 107 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2019 | 1369 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2007 | 894 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 113 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2017 | 502 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2007 | 484 | 0.060 |
Why?
|
| Plant Extracts | 2 | 2021 | 286 | 0.060 |
Why?
|
| Overweight | 1 | 2006 | 247 | 0.060 |
Why?
|
| Smoking Cessation | 3 | 2018 | 517 | 0.060 |
Why?
|
| Neoadjuvant Therapy | 1 | 2023 | 13 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 1609 | 0.060 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2023 | 20 | 0.060 |
Why?
|
| Models, Psychological | 1 | 2003 | 131 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 1371 | 0.050 |
Why?
|
| SEER Program | 1 | 2003 | 91 | 0.050 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2022 | 3 | 0.050 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2022 | 22 | 0.050 |
Why?
|
| Sick Role | 1 | 2002 | 6 | 0.050 |
Why?
|
| Administration, Intravesical | 1 | 2022 | 5 | 0.050 |
Why?
|
| Selection Bias | 1 | 2021 | 11 | 0.050 |
Why?
|
| Depressive Disorder | 1 | 2003 | 174 | 0.050 |
Why?
|
| Tissue Extracts | 1 | 2021 | 10 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 1039 | 0.050 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2021 | 21 | 0.050 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 1 | 2021 | 12 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 356 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2021 | 143 | 0.050 |
Why?
|
| Asbestos, Crocidolite | 1 | 2020 | 8 | 0.050 |
Why?
|
| Language | 1 | 2022 | 157 | 0.050 |
Why?
|
| Genomics | 1 | 2022 | 223 | 0.050 |
Why?
|
| beta Catenin | 1 | 2021 | 48 | 0.050 |
Why?
|
| alpha-Fetoproteins | 1 | 2020 | 31 | 0.050 |
Why?
|
| Genomic Instability | 1 | 2020 | 38 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2021 | 118 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2021 | 208 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 204 | 0.050 |
Why?
|
| Communication | 1 | 2022 | 180 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2011 | 286 | 0.050 |
Why?
|
| Nitrosamines | 1 | 2020 | 10 | 0.050 |
Why?
|
| Biopsy | 1 | 2020 | 164 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2021 | 219 | 0.040 |
Why?
|
| Lipoproteins, HDL | 1 | 2019 | 46 | 0.040 |
Why?
|
| Tobacco, Smokeless | 1 | 2019 | 18 | 0.040 |
Why?
|
| Triglycerides | 1 | 2019 | 138 | 0.040 |
Why?
|
| Family | 1 | 2020 | 173 | 0.040 |
Why?
|
| Guam | 1 | 2019 | 79 | 0.040 |
Why?
|
| Mycobacterium bovis | 1 | 2019 | 15 | 0.040 |
Why?
|
| China | 2 | 2012 | 196 | 0.040 |
Why?
|
| Base Sequence | 1 | 2021 | 997 | 0.040 |
Why?
|
| Fructose | 1 | 2018 | 22 | 0.040 |
Why?
|
| Sucrose | 1 | 2018 | 26 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 227 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2019 | 118 | 0.040 |
Why?
|
| Focus Groups | 1 | 2020 | 348 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2019 | 295 | 0.040 |
Why?
|
| Insulin | 1 | 2019 | 236 | 0.040 |
Why?
|
| Azoxymethane | 1 | 2017 | 7 | 0.040 |
Why?
|
| Enterocytes | 1 | 2017 | 4 | 0.040 |
Why?
|
| Norway | 2 | 2007 | 9 | 0.040 |
Why?
|
| HT29 Cells | 1 | 2017 | 45 | 0.040 |
Why?
|
| Models, Biological | 1 | 2021 | 677 | 0.040 |
Why?
|
| Mental Health | 1 | 2021 | 303 | 0.040 |
Why?
|
| Minority Groups | 1 | 2022 | 596 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 45 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 276 | 0.040 |
Why?
|
| Arizona | 2 | 2007 | 100 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 28 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2017 | 150 | 0.040 |
Why?
|
| Cyclooxygenase 2 | 1 | 2017 | 104 | 0.040 |
Why?
|
| Glucose | 1 | 2018 | 230 | 0.040 |
Why?
|
| Oncogene Proteins | 1 | 2016 | 21 | 0.040 |
Why?
|
| Multigene Family | 1 | 2016 | 106 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2016 | 63 | 0.030 |
Why?
|
| Pleural Effusion | 1 | 2016 | 8 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 259 | 0.030 |
Why?
|
| Genome, Human | 1 | 2016 | 135 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2016 | 151 | 0.030 |
Why?
|
| Osteopontin | 1 | 2016 | 36 | 0.030 |
Why?
|
| Acetylation | 1 | 2016 | 98 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 617 | 0.030 |
Why?
|
| Alleles | 1 | 2016 | 321 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2016 | 67 | 0.030 |
Why?
|
| Carbon Monoxide | 1 | 2015 | 34 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2017 | 661 | 0.030 |
Why?
|
| RNA Interference | 1 | 2016 | 243 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 225 | 0.030 |
Why?
|
| Cytokines | 1 | 2019 | 602 | 0.030 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2015 | 35 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2021 | 642 | 0.030 |
Why?
|
| Los Angeles | 2 | 2006 | 380 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2016 | 435 | 0.030 |
Why?
|
| Social Behavior | 1 | 2015 | 131 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 409 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 219 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 515 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2015 | 260 | 0.030 |
Why?
|
| Histones | 1 | 2015 | 190 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 2 | 2005 | 191 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2016 | 325 | 0.030 |
Why?
|
| Lactation | 1 | 2013 | 40 | 0.030 |
Why?
|
| Sunlight | 1 | 2013 | 47 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2012 | 149 | 0.030 |
Why?
|
| Seasons | 1 | 2013 | 112 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 90 | 0.030 |
Why?
|
| Hydroxyestrones | 1 | 2012 | 8 | 0.030 |
Why?
|
| Korea | 1 | 2012 | 43 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2016 | 1207 | 0.030 |
Why?
|
| Cognition | 1 | 2015 | 398 | 0.030 |
Why?
|
| Food Analysis | 1 | 2011 | 30 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2011 | 65 | 0.020 |
Why?
|
| Phenotype | 1 | 2014 | 689 | 0.020 |
Why?
|
| Flavonoids | 1 | 2012 | 87 | 0.020 |
Why?
|
| Specimen Handling | 1 | 2011 | 56 | 0.020 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2011 | 29 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2013 | 208 | 0.020 |
Why?
|
| Placebos | 1 | 2010 | 37 | 0.020 |
Why?
|
| Anxiety | 1 | 2017 | 754 | 0.020 |
Why?
|
| Milk Proteins | 1 | 2010 | 29 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 859 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 893 | 0.020 |
Why?
|
| Disease Progression | 1 | 2012 | 601 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2011 | 182 | 0.020 |
Why?
|
| Apoptosis | 1 | 2017 | 1398 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2011 | 753 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 352 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2017 | 1908 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 610 | 0.020 |
Why?
|
| Pain | 1 | 2009 | 251 | 0.020 |
Why?
|
| Hormone Replacement Therapy | 1 | 2005 | 41 | 0.020 |
Why?
|
| Nutrition Surveys | 1 | 2007 | 242 | 0.020 |
Why?
|
| Menopause | 1 | 2005 | 56 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2005 | 18 | 0.020 |
Why?
|
| Reference Values | 1 | 2005 | 212 | 0.020 |
Why?
|
| Mastectomy | 1 | 2005 | 15 | 0.020 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2005 | 56 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2005 | 215 | 0.020 |
Why?
|
| Insurance Claim Reporting | 1 | 2003 | 4 | 0.010 |
Why?
|
| Fourier Analysis | 1 | 2003 | 43 | 0.010 |
Why?
|
| Periodicity | 1 | 2003 | 34 | 0.010 |
Why?
|
| Body Weight | 1 | 2005 | 434 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 583 | 0.010 |
Why?
|
| Affect | 1 | 2003 | 152 | 0.010 |
Why?
|
| Comorbidity | 1 | 2003 | 623 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2005 | 803 | 0.010 |
Why?
|